Department of Clinical Pharmacology and Therapeutics, College of Medicine, Kyung Hee University, Seoul 02447, Republic of Korea.
Department of Clinical Pharmacology and Therapeutics, College of Medicine, Kyung Hee University, Seoul 02447, Republic of Korea; School of Biomedical Engineering, College of Health Science, Korea University, Seoul 02841, Republic of Korea.
Biosens Bioelectron. 2019 Mar 1;128:166-175. doi: 10.1016/j.bios.2018.12.046. Epub 2019 Jan 2.
The filtration effect improves the impedance change through specific binding of target molecules in plasma, and decreases this change by nonspecific binding of matrix factors in plasma (i.e., matrix effect). A difference in dielectrophoresis (DEP) forces applied to target molecules and matrix factors causes the filtration effect. An optimized DEP force affects target molecules, which remain in the reaction region of an interdigitated microelectrode (IME) sensor. Various matrix factors, which are larger than the target molecules, are influenced by a strong DEP force and are filtered out of the reaction region. To demonstrate the filtration effect, the matrix effect was confirmed in standard plasma and in phosphate-buffered saline, based on the detection of amyloid beta (Aβ), an Alzheimer's disease (AD)-associated peptide. The filtration effect was verified using the matrix effect factor (MEF), which was calculated from the impedance change values in different detection environments. In standard plasma, the MEF value decreased by approximately 78.12%, and in buffer with heterogeneous Aβ, by approximately 75.43%. Plasma from patients with AD and normal controls (NCs) was analyzed using the value of the impedance change by the filtration effect. The impedance change was enhanced approximately 1.52 ± 0.03-fold in AD plasma, but declined approximately 0.90 ± 0.03-fold in NC plasma. This difference tendency by the filtration effect was the disease evaluation index and used as an important criterion that distinguished between the AD and NC plasma. Plasma-based AD diagnosis may be possible, based on the filtration effect.
过滤效应通过在血浆中特异性结合靶分子来改善阻抗变化,并通过在血浆中非特异性结合基质因子(即基质效应)来降低这种变化。施加于靶分子和基质因子的差分介电泳 (DEP) 力引起过滤效应。优化的 DEP 力会影响靶分子,这些分子会留在叉指微电极 (IME) 传感器的反应区域中。各种基质因子比靶分子大,会受到强 DEP 力的影响,并被过滤出反应区域。为了证明过滤效应,根据阿尔茨海默病 (AD) 相关肽淀粉样β (Aβ) 的检测,在标准血浆和磷酸盐缓冲盐水中证实了基质效应。使用基质效应因子 (MEF) 验证了过滤效应,该因子是根据不同检测环境中的阻抗变化值计算得出的。在标准血浆中,MEF 值下降了约 78.12%,在含有异质 Aβ 的缓冲液中下降了约 75.43%。使用过滤效应的阻抗变化值分析 AD 患者和正常对照 (NC) 的血浆。在 AD 血浆中,阻抗变化增强了约 1.52±0.03 倍,但在 NC 血浆中下降了约 0.90±0.03 倍。这种由过滤效应引起的差异趋势是疾病评估指标,并用作区分 AD 和 NC 血浆的重要标准。基于过滤效应,可能可以进行基于血浆的 AD 诊断。